Format

Send to

Choose Destination
Med Microbiol Immunol. 2015 Jun;204(3):247-54. doi: 10.1007/s00430-015-0388-z. Epub 2015 Mar 20.

The history of vaccination against cytomegalovirus.

Author information

1
Emeritus Professor of Pediatrics, University of Pennsylvania, 4650 Wismer Road, Doylestown, PA, 18902, USA, Stanley.Plotkin@vaxconsult.com.

Abstract

Cytomegalovirus vaccine development started in the 1970s with attenuated strains. In the 1980s, one of the strains was shown to be safe and effective in renal transplant patients. Then, attention switched to glycoprotein gB, which was shown to give moderate but transient protection against acquisition of the virus by women. The identification of the pp65 tegument protein as the principal target of cellular immune responses resulted in new approaches, particularly DNA, plasmids to protect hematogenous stem cell recipients. The subsequent discovery of the pentameric protein complex that generates most neutralizing antibodies led to efforts to incorporate that complex into vaccines. At this point, there are many candidate CMV vaccines, including live recombinants, replication-defective virus, DNA plasmids, soluble pentameric proteins, peptides, virus-like particles and vectored envelope proteins.

PMID:
25791890
DOI:
10.1007/s00430-015-0388-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center